Immunic, Inc. Banner Image

Immunic, Inc. has reached its limit for free report views

Work for Immunic, Inc.? Upgrade Your Profile and unlock all your annual reports.

Immunic, Inc.

  • Ticker IMUX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Immunic, Inc. Logo Image
  • 11-50 Employees
  • Based in New York City, New York
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, isMore a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function.
Immunic, Inc.

Most Recent Annual Report

Immunic, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Immunic, Inc. has reached its limit for free report views.

Older/Archived Annual Reports